— 2001 —
Ahmed SA, Byrne MP, Jensen M, Hines HB, Brueggeman E, Smith LA. 2001. Enzymatic autocatalysis of botulinum A neurotoxin. J Prot Chem 20:221-231.
Blow JA, MJ Turell, Silverman AL, Walker ED. 2001. Stercorarial shedding and transtadial transmission of hepatitis B virus by common bed bugs (Hemiptera: Cimicidae). J MeD Entomol 38:694-700.
Bray M. 2001. The role of type 1 interferon response in the resistance of mice to filovirus infection. J Gen Virol 82:1365-1373.
Bray M, Hatfill S, Hensley L, Huggins JW. 2001. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol 125:243-253.
Cieslak TJ. 2001. Medical consequences of biological warfare: The ten commandments of management. Mil Med 166:11-12.
Coffman JD, Zhu J, Roach JM, Bavari S, Ulrich RG, Giardina SL. 2001. Production and purification of a recombinant staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli. Prot Expr Purif 24:302-312.
Culpepper RC, Pratt WD. 2001. Advances in medical biological defense technology. Clin Lab Med 21:679-689.
DeShazer D, Waag DM, Fritz DL, Woods DE. 2001. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence factor. Microb Pathogen 30:253-269.
Dohm DJ, Turell MJ. 2001. Effect of incubation at overwintering temperatures on the replication of West Nile virus in New York Culex pipiens (Diptera:Culicidae). J Med Entomol 38:462-464.
Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM, Chanh TC. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect Immun 69:1172-1177.
Fellows PF, Linscott MK, Ivins BE, Pitt MLM, Rossi CA, Gibbs PH, Friedlander AM. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
Gibb TR, Norwood DA, Woolen N, Henchal EA. 2001. Development and evaluation of a fluorogenic 5'-nuclease assay to detect and differentiate between Ebola Zaire and Ebola Sudan. J Clin Microbiol 39:4125-4130.
Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK. 2001. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 125:233-242.
Hale ML. 2001. Microtiter-based assay for evaluating the biological activity of ribosome-inactivating proteins. Pharmacol Toxicol 88:255-260.
Hale ML, Campbell TA, Campbell YG, Fong SE, Stiles BG. 2001. Development of a time-resolved immunofluorometric assay for quantitation of mucosal and systemic antibody responses. J Immunol Meth 257:83-92.
Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, Ludwig GV. 2001. Onset and duration of protective immunity to IA/B and IE strains of Venezuelan equine encephalitis virus in vaccinated mice. Vaccine 20:616-622.
Hawley RJ, Pittman PR, Nerges JA. 2001. Maximum containment for researchers exposed to biosafety level 4 agents, pp 35-53. In JY Richmond (ed), Anthology of Biosafety: II, Publication committee of the American Biological Safety Association, Mundalein, IL.
Hawley RJ, Eitzen Jr EM. 2001. Protection against biological warfare agents, pp 1161-1167. In SS Block (ed), Disinfection, Sterilization, and Preservation, Lippincott Williams & Wilkins, Philadelphia PA.
Hawley RJ. 2001. Biosafety training - a practical, realistic, and reasonable approach. The Loop, newsletter of the National Registry of Microbiologists. 27:2-3.
Hawley RJ, Eitzen Jr EM. 2001. Biological weapons - a primer for microbiologists. Ann Rev Microbiol 55:235-253.
Henchal EA, Teska JD, Ludwig GV, Shoemaker DR, Ezzell JW. 2001. Current laboratory methods for biological threat agent identification. Clin Lab Med 21:661-678.
Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, Smith JF, Jahrling PB, Schmaljohn AL. 2001. Marburg virus vaccines: Comparing classical and new approaches. 20:586-593.
Hooper JW, Li D. 2001. Vaccines against hantaviruses, pp 171-191. In CS Schmaljohn, ST Nichol (ed), Current Topics in Microbiology and Immunology, Vol 256, Springer-Verlag, Berlin.
Hooper JW, Custer DM, Thompson E, Schmaljohn CS. 2001. DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys. J Virol 75:8469-8477.
Hooper JW, Larsen T, Custer DM, Schmaljohn CS. 2001. A lethal disease model for hantavirus pulmonary syndrome. Virology 289:6-14.
Kortepeter MG, Krauss MR. 2001. Tuberculosis infection after humanitarian assistance, Guantanamo Bay, 1995. Mil Med 166:116-120.
Kortepeter MG, Cieslak TJ, Eitzen Jr EM. 2001. Bioterrorism. J Environ Hlth 63:21-24.
Krakauer T. 2001. Suppression of endotoxin- and staphylococcal exotoxin-induced cytokines and chemokines by a phospholipase C inhibitor in human peripheral blood mononuclear cells. Clin Diag Lab Immunol 8:449-453.
Krakauer T, Russo C. 2001. Serum cytokine levels and antibody response to influenza vaccine in the elderly. Immunopharmacol Immunotoxicol 1:35-41.
Krakauer T, Li BQ, Young HA. 2001. The flavonoid baicalin inhibits staphylococcal superantigen-induced inflammatory cytokines and chemokines. FEBS Lett 500:52-55.
LeClaire RD, Bavari S. 2001. Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother 45:460-463.
Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. 2001. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 69:5709-5715.
Ludwig GV, Turell MJ, Vogel P, Kondig JP, Kell W, Smith JF, Pratt WD. 2001. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am J Trop Med Hyg 64:49-55.
Marty AM, Conran RM, Kortepeter MG. 2001. Recent challenges in infectious diseases. Biological pathogens as weapons and emerging endemic threats. Clin Lab Med 21:411-420.
Marvaud J-C, Smith T, Hale ML, Popoff MR, Smith LA, Stiles BG. 2001. Clostridium perfringens iota-toxin: Mapping of receptor binding and LA docking domains on LB. Infect Immun 69:2435-2441.
O'Quinn AL, Wiegand EM, Jeddeloh JA. 2001. Burkholderia pseudomallei kills the nematode Caenorhabditis elegans using an endotoxin-mediated paralysis. Cell Microbiol 3:381-393.
Olson MA. 2001. Electrostatic effects on the free-energy balance in folding a ribosome-inactivating protein. Biophys Chem 91:219-229.
Olson MA. 2001. Calculations of free-energy contributions to protein-RNA complex stabilization. Biophys J 81:1841-1853.
Pastel RH. 2001. Collective behaviors: Mass panic and outbreaks of multiple unexplained symptoms. Mil Med 166:44-46.
Pastel RH, Mulvaney J. 2001. Fear of radiation in U.S. military medical personnel. Mil Med 166:80-82.
Pitt MLM, Little SF, Ivins BE, Fellows P, Barth J, Hewetson JF, Gibbs P, Dertzbaugh M, Friedlander AM. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773.
Pittman PR, Mangiafico JA, Rossi CA, Cannon TL, Gibbs PH, Parker GW, Friedlander AM. 2001. Anthrax vaccine: Increasing intervals between the first two doses enhances antibody response in humans. Vaccine 19:213-216.
Pless DD, Torres ER, Reinke EK, Bavari S. 2001. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 69:570-574.
Poli MA, FJ Lebeda. 2001. An overview of clostridial toxins, pp 293-304. In EJ Massaro (ed), Handbook of Neurotoxicology, Humana Press Inc, Totowa, NJ.
Pushko P, Geisbert J, Parker M, Jahrling P, Smith J. 2001. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75:11677-11685.
Pushko P, Bray M, Ludwig GV, Parker D, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2001. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153.
Sardelis MR, Turell MJ. 2001. Ochlerotatus j. japonicus in Frederick County, Maryland: Discovery, distribution, and vector competence for West Nile virus. J Am Mosq Control Asso 17:137-141.
Sardelis MR, Turell MJ, Dohm DJ, O'Guinn ML. 2001. Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus. Emerg Infect Dis 7:1018-1022.
Schmidt JJ, Stafford RG, Millard CB. 2001. High throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Anal Biochem 296:130-137.
Smee DF, Bray M, Huggins JW. 2001. Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent. Antivir Chem Chemother 12:251-258.
Smith DR, Rossi CA, Kijek TM, Henchal EA, Ludwig GV. 2001. Comparison of dissociation-enhanced lanthanide fluorescent immunoassays to enzyme-linked immunosorbent assays for detection of staphylococcal enterotoxin B, Yersinia pestis-specific F1 antigen, and Venezuelan equine encephalitis virus. Clin Diag Lab Immunol 8:1070-1075.
Srinivasan A, Kraus CN, DeShazer D, Becker PM, Dick JD, Spacek L, Bartlett JG, Byrne WR, Thomas DL. 2001. Glanders in a military research microbiologist. N Eng J Med 345:256-258.
Steele KE, Stabler K, VanderZanden L. 2001. Cutaneous DNA vaccination against Ebola virus by particle bombardment: Histopathology and alteration of CD3-positive dendritic epidermal cells. Vet Pathol 38:203-215.
Steele K, Crise B, Kuehne A, Kell W. 2001. Ebola virus glycoprotein demonstrates differential cellular localization in infected cell types of nonhuman primates and guinea pigs. Arch Pathol Lab Med 125:625-630.
Stiles BG, Garza AR, Ulrich RG, Boles JW. 2001. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun 69:2031-2036.
Turell MJ, O'Guinn ML, Dohm DJ, Jones JW. 2001. Vector competence of North American mosquitoes (Diptera:Culicidae) for West Nile virus. J Med Entomol 38:130-134.
Turell MJ, Sardelis MR, Dohm DJ, O'Guinn ML. 2001. Potential North American vectors of West Nile virus. Ann NY Acad Sci 951:317-324.
Welkos SL, Little SF, Friedlander A, Fritz D, Fellows P. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685.
Wilson JA, Hart MK. 2001. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J Virol 75:2660-2664.
Wilson JA, Bray M, Bakken R, Hart MK. 2001. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286:384-390.
Wilson JA, Bosio CM, Hart MK. 2001. Ebola virus: The search for vaccines and treatments. Cell Mol Life Sci 58:1826-1841.
Zaucha GM, Jahrling PB, Geisbert TM, Swearengen JR, Hensley L. 2001. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest 81:1581-1600
Return to top